M Rotondi1, C Virili2, S Pinto1, F Coperchini1, L Croce1,3, N Brusca4,5, M Centanni2, L Chiovato6,7. 1. Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Via S. Maugeri 4, 27100, Pavia, Italy. 2. Endocrinology Unit, Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Latina, Italy. 3. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. 4. Department of Medical and Surgical Sciences and Biotechnology, Sapienza University of Rome, Rome, Italy. 5. Department of Experimental Medicine, "Sapienza" University of Rome, Rome, Italy. 6. Unit of Internal Medicine and Endocrinology, Laboratory for Endocrine Disruptors, Istituti Clinici Scientifici Maugeri IRCCS, Via S. Maugeri 4, 27100, Pavia, Italy. luca.chiovato@icsmaugeri.it. 7. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy. luca.chiovato@icsmaugeri.it.
Abstract
PURPOSE: Graves' disease (GD) can present as an isolated disease (iGD) or in association with other autoimmune diseases (aGD). The aim of this study, performed in two Endocrine referral centers settled in different geographical areas of Italy, was to compare the anthropometric, clinical, and biochemical phenotype of iGD patients with that of the aGD ones. METHODS: Clinical history, physical examination data, serum levels of TSH, FT4, FT3, thyroglobulin (TgAb), thyroid-peroxidase (TPOAb) and TSH-receptor (TRAb) antibody, presence of Graves' orbitopathy (GO), and thyroid ultrasound examination at disease diagnosis were recorded. RESULTS: 68 aGD and 136 iGD patients were consecutively recruited. At diagnosis, aGD and iGD patients did not differ for F/M ratio, age at presentation, thyroid function parameters, serum levels of TRAb, TgAb, TPOAb, presence of GO, and thyroid volume. The serum levels of TRAb were strongly correlated with the circulating concentrations of both FT3 (ρ = 0.667; p < 0.0001) and FT4 (ρ = 0.628; p < 0.001) in iGD patient, but not in the aGD ones (FT3: ρ = 0.231; p = 0.058; FT4: ρ = 0.096; p = 0.435). Compared with iGD patients, the aGD ones displayed a higher rate of transition from the previous hypothyroidism to hyperthyroidism (χ2 = 6.375; p = 0.012). CONCLUSION: Despite similar anthropometric, clinical, and biochemical features at diagnosis, aGD patients display a higher rate of transition from a thyroid functional status to the other as compared with iGD patients.
PURPOSE:Graves' disease (GD) can present as an isolated disease (iGD) or in association with other autoimmune diseases (aGD). The aim of this study, performed in two Endocrine referral centers settled in different geographical areas of Italy, was to compare the anthropometric, clinical, and biochemical phenotype of iGDpatients with that of the aGD ones. METHODS: Clinical history, physical examination data, serum levels of TSH, FT4, FT3, thyroglobulin (TgAb), thyroid-peroxidase (TPOAb) and TSH-receptor (TRAb) antibody, presence of Graves' orbitopathy (GO), and thyroid ultrasound examination at disease diagnosis were recorded. RESULTS: 68 aGD and 136 iGDpatients were consecutively recruited. At diagnosis, aGD and iGDpatients did not differ for F/M ratio, age at presentation, thyroid function parameters, serum levels of TRAb, TgAb, TPOAb, presence of GO, and thyroid volume. The serum levels of TRAb were strongly correlated with the circulating concentrations of both FT3 (ρ = 0.667; p < 0.0001) and FT4 (ρ = 0.628; p < 0.001) in iGDpatient, but not in the aGD ones (FT3: ρ = 0.231; p = 0.058; FT4: ρ = 0.096; p = 0.435). Compared with iGDpatients, the aGD ones displayed a higher rate of transition from the previous hypothyroidism to hyperthyroidism (χ2 = 6.375; p = 0.012). CONCLUSION: Despite similar anthropometric, clinical, and biochemical features at diagnosis, aGD patients display a higher rate of transition from a thyroid functional status to the other as compared with iGDpatients.
Authors: Julio C Bai; Michael Fried; Gino R Corazza; Detlef Schuppan; Michael Farthing; Carlo Catassi; Luigi Greco; Henry Cohen; Carolina Ciacci; Rami Eliakim; Alessio Fasano; Andrea González; Justus H Krabshuis; Anton LeMair Journal: J Clin Gastroenterol Date: 2013-02 Impact factor: 3.062
Authors: C Shigemasa; Y Mitani; S Taniguchi; T Adachi; Y Ueta; K Urabe; S Miyazaki; T Tanaka; A Yoshida; H Mashiba Journal: Arch Intern Med Date: 1990-05
Authors: L Bartalena; E Masiello; F Magri; G Veronesi; E Bianconi; F Zerbini; M Gaiti; E Spreafico; D Gallo; P Premoli; E Piantanida; M L Tanda; M Ferrario; P Vitti; L Chiovato Journal: J Endocrinol Invest Date: 2016-07-27 Impact factor: 4.256
Authors: William L Neumann; Elizabeth Coss; Massimo Rugge; Robert M Genta Journal: Nat Rev Gastroenterol Hepatol Date: 2013-06-18 Impact factor: 46.802
Authors: F P Pellegrini; M Marinoni; V Frangione; A Tedeschi; V Gandini; F Ciglia; L Mortara; R S Accolla; L Nespoli Journal: Clin Exp Immunol Date: 2012-09 Impact factor: 4.330
Authors: Yi Xu; Songxia Peng; Li Qin; Dianjing Sun; Jianlin Geng; Qingqing Liu Journal: Evid Based Complement Alternat Med Date: 2022-07-06 Impact factor: 2.650
Authors: Jason Phowira; Katherine L Coffey; Peter H Bartholomew; Nicholas Vennart; Matheus Moreira; Hannah Emerson; David Kennedy; Jolanta U Weaver Journal: Front Endocrinol (Lausanne) Date: 2022-03-09 Impact factor: 5.555
Authors: V Guarnotta; G Pillitteri; G Gambino; S Radellini; E Vigneri; G Pizzolanti; C Giordano Journal: J Endocrinol Invest Date: 2020-10-24 Impact factor: 4.256
Authors: S Ippolito; C Cusini; P Lasalvia; F Gianfagna; G Veronesi; D Gallo; E Masiello; P Premoli; J Sabatino; A Mercuriali; A Lai; E Piantanida; M L Tanda; L Bartalena Journal: J Endocrinol Invest Date: 2020-12-21 Impact factor: 4.256